Clinical Trial: Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07637734) titled 'Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)' on May 27.

Brief Summary: This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Common Warts Common Warts (Verruca Vulgaris) Human Papilloma Virus (HPV) Warts

Intervention: COMBINATION_PRODUCT: VP-102 (US) / TO-208 (Japan)

A single-use applicator and applied in suff...